Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
| ▸ | GABRE | P78334 | 6/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31271664 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL4538233 | 0.94 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL31165703 | 0.84 | LCK (0.55) | ALDH1A1GABRG2GABRB3GABRA5GABRA2 | |
| SCHEMBL21885738 | 0.83 | ALOX15 (0.50) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL2201127 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL30712292 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL30712301 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL1808295 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL2001591 | 0.78 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2GABRA2GABRB2CYP1A2 | |
| SCHEMBL31649767 | 0.78 | GABRA2 (0.48) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-111196804-A | TGF- β R1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-5470999-A | Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity | ALLERGAN, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| US-5451605-A | Treating skin disorders | ALLERGAN, INC. (US) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | ALDH1A1 4576/4885SMN1; SMN2 2723/4885GABRG2 1505/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | ALDH1A1 3122/4885SMN1; SMN2 3575/4885GABRG2 4748/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | ALDH1A1 1563/4885SMN1; SMN2 4067/4885GABRG2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.